Compare Quantum Computing Inc (QUBT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantum Computing Inc vs Viatris Inc — how do they compare? Quantum Computing Inc trades at $7.91 (market cap $1.85B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 11.1× Quantum Computing Inc's market cap, and Viatris Inc pays a 2.73% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| QUBT | VTRS | |
|---|---|---|
Market Cap | $1.85B | $20.50B |
Sector | Technology | Health |
52-Week High | $24.62 | $17.59 |
52-Week Low | $6.31 | $8.74 |
Enterprise Value | $871.49M | $32.71B |
Dividend Yield | — | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
